Brug af transkraniel fotobiomodulation til at forbedre kognition og selvrapporterede resultater hos overlevende af børnekræft
Survivors of childhood cancer are at greater risk for long-term cognitive impairments that include attention, executive function, intelligence, memory, and processing speed. The participants are a survivor of acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma (HL). Because of your treatment the participant may have developed trouble with thinking and learning.
Primary Objective
To evaluate the feasibility of using home-based tPBM paired with remote cognitive training to improve cognitive performance in survivors of ALL and HL.
Secondary Objectives
To estimate the potential efficacy of alpha and gamma frequency tPBM on cognitive performance in survivors of ALL and HL.
Exploratory Objectives
To estimate the effects of home-based tPBM paired with remote cognitive training on patient reported symptoms of executive dysfunction, sleep, depression, anxiety, fatigue, and pain in survivors of ALL and HL.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Survivors with ALL and HL with identified executive function impairment will be randomized to receive stimulation with alpha tPBM + cognitive training, gamma tPBM + cognitive training or sham tPBM + cognitive training three days per week for a 2-month intervention period The tPBM will be applied to nodes in the default mode network.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38105
- St. Jude Children's Research Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Completed treatment for acute lymphoblastic leukemia (ALL) or Hodgkin's Lymphoma (HL) at SJCRH.
- Enrolled in SJLIFE, and less than 21 years of age at diagnosis.
- 18 years of age or older at time of enrollment.
- 2 years or greater post-treatment completion of cancer directed therapy and not currently receiving any cancer directed therapy.
- English language proficiency.
- Access to WiFi.
- Executive dysfunction defined as having an age-adjusted standard score less than 16th percentile on objectively assessed cognitive test or patient-reported executive dysfunction defined as having a standard score greater than 84th percentile within 3 years of time of enrollment.
Exclusion Criteria:
- Estimated intelligence score less than 80.
- Currently taking medication intended to treat neurocognitive impairment (i.e., stimulants).
- Major psychiatric condition.
- Alcohol abuse in the past year (AUDIT) [greater than or equal to 13 for women and greater than or equal to 15 for men]. The Alcohol Use Disorders Identification Test (AUDIT) will be used to screen for individuals who have active alcohol-use disorders.
- Drug abuse in the past year (DAST-10) [ greater than or equal to 3 for women or men] The Drug Abuse Screen Test (DAST-10) will be used to screen for individuals with active drug abuse.
- History of neurologic condition or genetic disorder associated with neurocognitive impairment unrelated to cancer diagnosis or treatment.
- Enrolled on another independent cognitive intervention protocol within the last year.
- Female participants who are pregnant or lactating (determined by participant self-report due to the remote nature of this study)
- Tattoo or artificial marking in the area where the device will be positioned.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Enhedens gennemførlighed
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Tredobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: alpha tPBM + cognitive training
three days per week for a 2-month intervention period (5 ALL and 5 HL) |
The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
Andre navne:
|
|
Eksperimentel: gamma tPBM + cognitive training
three days per week for a 2-month intervention period (5 ALL and 5 HL) |
The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
Andre navne:
|
|
Eksperimentel: sham tPBM + cognitive training
Sham stimulations will act as the control for this study three days per week for a 2-month intervention period (5 ALL and 5 HL) |
The Vielight NeURO device delivers 810 nm near infrared light via four (4) transcranial LED modules. The LED modules target brain regions associated with a variety of cognitive functions. It can deliver light at two frequencies: Alpha (10 Hz) and Gamma (40 Hz). Alpha oscillations are prominent in healthy brains during wakeful resting and gamma oscillations are associated with activities associated with focus, memory, and cognition.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants who completed a two-month trial of paired photobiomodulation (PBM) therapy and cognitive training
Tidsramme: 4 months after participant enrollment
|
The trial will be considered feasible if at least 15 of 30 survivors are able to complete 18 of 24 sessions (PBM along with cognitive training). |
4 months after participant enrollment
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
CNS Vital Signs adaptions of the Rey auditory verbal learning test (RVLT).
Tidsramme: 2 month and 4 months after enrollment
|
RVLT is a test that evaluate working memory. |
2 month and 4 months after enrollment
|
|
CNS Vital Signs adaptions of the Rey visual design learning (RVDL) test.
Tidsramme: 2 month and 4 months after enrollment
|
RVDL is a test that evaluate working memory. |
2 month and 4 months after enrollment
|
|
CNS Vital Signs implemented Stroop color and word test.
Tidsramme: 2 month and 4 months after enrollment
|
The Stroop test is a test that evaluates Inhibitory control. |
2 month and 4 months after enrollment
|
|
CNS Vital Signs implemented Shifting Attention Test.
Tidsramme: 2 month and 4 months after enrollment
|
The Shifting attention test and Stroop test are tests that are used to measure cognitive flexibility. |
2 month and 4 months after enrollment
|
|
CNS Vital Signs implementation of the Continuous Performance Test (CPT).
Tidsramme: 2 month and 4 months after enrollment
|
The CPT test is a test that evaluates attention. |
2 month and 4 months after enrollment
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Nicholas Phillips, MD,PhD, St. Jude Children's Research Hospital
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- PBMP
- NCI-2022-09116 (Anden identifikator: NCI Clinical Trial Registration Program)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .